Mr BN is a 24-year-old Caucasian with a chief complaint of choking and shortness of breath while sleeping. He presented panic attacks during sleep, with shortness of breath, chest pain, dyspnea, choking, paresthesias, sweating, tachycardia, and severe fear of dying. His laboratory tests were within normal limits. His clinical picture was marked by intense fear of having a panic attack while sleeping. He developed an avoidant pattern of falling asleep while working at his usual daily activities during the night. A diurnal drowsiness resulted in difficulty in maintaining concentration.
Case Report 2
Mr BN is a 24-year-old Caucasian with a chief complaint of choking and shortness of breath while sleeping. He presented panic attacks during sleep, with shortness of breath, chest pain, dyspnea, choking, paresthesias, sweating, tachycardia, and severe fear of dying. His laboratory tests were within normal limits. His clinical picture was marked by intense fear of having a panic attack while sleeping. He developed an avoidant pattern of falling asleep while working at his usual daily activities during the night. A diurnal drowsiness resulted in difficulty in maintaining concentration.
We instituted treatment with nortriptyline, with a gradual increase of the dosage. At 20 mg daily, the patient experienced a lessening in the frequency and intensity of his panic attacks, and the respiratory symptoms remitted. A complete remission of the panic attacks, agoraphobia, and anticipatory anxiety was achieved at 75 mg daily, and the patient has been without any panic attacks at 1year follow-up.
Nocturnal panic attacks are common and often neglected. These case reports suggest major findings in regard to them: 1) the prominent respiratory symptoms; 2) the overlapping with sleep disorders symptoms; and 3) a change in the pattern of diurnal panic attacks, from spontaneous situational. A hypothesis to account for these findings exists in the pathophysiology of the sleep, when blood carbon dioxide (CO 2 ) levels rise significantly (3) . The panic disorder patients, who have heightened CO 2 sensitivity (2,3), according to Klein's false suffocation alarm theory (4), start a cycle in which enhanced CO 2 leads to more frequent sighing in an attempt to reduce arterial CO 2 levels (3).
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Carbon Dioxide Test in Respiratory Panic Disorder Subtype
Dear Editor:
Inhaling high concentrations of carbon dioxide (CO 2 ) has consistently been shown to provoke panic attacks in patients with panic disorder (PD) (1). Our objective was to verify the sensitivity to CO 2 challenge of PD patients with respiratory and nonrespiratory subtypes. We randomly selected 20 PD patients (diagnosed according to DSM-IV criteria) at the Laboratory of Panic and Respiration in Rio de Janeiro. The subjects signed a voluntary written inform consent, and the protocol was approved by our local ethical committee.
To participate, we required the subjects to be at least 18 years old, to report at least 3 panic attacks in the last 2 weeks, and to be free of psychotropic drugs for at least 1 week. Exclusion criteria were any other current mental or major medical disorders, pregnancy, and substance abuse within the prior 6 months. We assessed the clinical symptoms of the most severe recent panic attack before the initial test to classify the subjects as respiratory and nonrespiratory subtypes (2) .
The test was double-blind, and 2 mixtures were used: 1) 35% CO 2 and 65% O 2 , and 2) 100% atmospheric compressed air, given 20 minutes apart. Participants were asked to exhale as fully as possible, place the mask on their face, and take a fast, vital-capacity breath, inhaling either the 35% CO 2 mixture or the atmospheric compressed air. They were asked to hold their breath for 8 seconds. Immediately after, they were asked to repeat the fast, vital-capacity breath and hold it again for 8 seconds. After 20 minutes, this test was repeated with the other gas mixture. We repeated the tests in 2 weeks. During that time, no participants received any psychotropic drugs.
We defined a CO 2 -induced panic attack as follows: 1) 4 or more DSM-IV panic attack symptoms, 2) at least 1 DSM-IV cognitive symptom (for example, fear of dying or losing control), 3) the sensation of a spontaneous panic attack, and 4) agreement of 2 investigators. To compare the differences between the presence of panic attacks after CO 2 challenge, we used Fisher's exact test.
The patients were 12 women and 8 men with a mean (SD) age of 35.8 (6.9) years. In the respiratory subtype there were 6 women and 5 men with a mean (SD) age of 33.4 (9.8) years, and in the nonrespiratory subtype there were 6 women and 3 men with a mean (SD) age of 37.8 (4.3) years. There was no difference between the 2 groups in mean age (t-test, P = 0.677).
In the first CO 2 challenge test, 7/11 (63.6%) respiratory PD patients and 3/9 (33.3%) nonrespiratory PD patients had a panic attack (Fisher's exact test, P = 0.024). In the second CO 2 challenge (after 2 weeks), 9/11 (81.8%) respiratory PD patients and 3/9 (33.3%) nonrespiratory PD patients had a panic attack (Fisher's exact test, P = 0.011). No patient had a panic attack with atmospheric air.
Our results are similar to those of Biber and Alkin (1). Klein's theory (3) could explain why the respiratory panic subtype patients had higher rates of panic attacks than those of the nonrespiratory subtype, indicating greater sensitivity to CO 2 . The characterization of PD subtypes through CO 2 challenge may be useful in elucidating the biological features, course, and response to treatment of PD.
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Depression in Multiple Sclerosis Associated With Interferon Beta-1a (Rebif)
The lifetime risk of depression in those with multiple sclerosis (MS) is very high, with some estimates exceeding 50% (1) . In initial trials of interferon beta-1b, there were several suicide attempts and 1 completed suicide, compared with no suicides in the placebo group (2) . Since that time, there has been concern that interferon treatment can cause depressive symptoms, and the product monograph suggests that patients treated with interferon beta-1b be "informed that depression and suicidal ideation may be a side effect of treatment" (3) . Some recent studies have not confirmed this association. The following case suggests a causal link between interferon beta-1a treatment of MS and major depressive disorder.
Case Report
A 42-year-old Caucasian woman diagnosed in March 2001 with clinically definite relapsing and remitting MS was started on interferon beta-1a therapy the same month. The Center for Epidemiological Studies Depression Rating Scale (CES-D) score (4, 5) , obtained prior to initiation of interferon beta-1a, was 4. A second rating, obtained in September 2001, was 28. The patient described a 5month history of sustained depressed mood, crying spells, sleep disturbance (early morning awakening), hostility, amotivation, apathy, no libido, poor concentration and short-term memory, and a depressed cognitive shift (that is, feelings of hopelessness and guilt). Regarding psychiatric history, the patient had never seen a psychiatrist or mental health professional prior to the consultation in December 2001. However, she did acknowledge a remote history of bulimia nervosa in her teens. Medical history and family history were not contributory to her depression.The patient was started on citalopram in November 2001, and 6 weeks after initiation of the antidepressant she noticed a decrease in sadness and hostility. Her sleep also improved. A CES-D was repeated in December 2001 and her score was 23.
The 5 point reduction in CES-D scores was modest, but there was a significant clinical reduction in depressive symptomatology, and she was able to continue with interferon beta-1a treatment. It has been shown that patients with MS who have depression often discontinue therapy (6); this patient felt well enough to continue with her prescribed diseasemodifying therapy.
An analysis of depression data from the PRISMS clinical trial showed no evidence of increased depressive symptomatology associated with interferon beta 1a (the median change in CES-D score after 6 months of treatment was 0) (7) . While the PRISMS trial provides evidence that depression must be a rare event during interferon treatment, clinicians should maintain an index of suspicion. If significant depressive symptoms arise, pharmacotherapeutic treatment appears to be an option. In our case, there was a beneficial response to selective serotonin reuptake inhibitor (SSRI) therapy (citalopram). Recent studies have shown that prophylactic treatment with paroxetine is an effective strategy to minimize depression induced by treatment with interferon alfa-2b for malignant melanoma (8) . It is also evident that swift detection and treatment can reduce the impact of major morbidity associated with MS.
